瑞舒伐他汀治疗冠心病患者疗效观察及对患者凝血、血液流变学、血脂、细胞因子水平的影响

摘要

Objective To investigate the effect of rosuvastatin in the treatment of coronary heart disease and its effects on blood rheol-ogy, blood rheology, blood lipids and cytokine levels.Methods 104 cases were randomly equally assigned into the observation group (n =52) and the control group (n =52) .The control group was treated with conventional symptomatic treatment, while the observa-tion group was treated with rosuvastatin along with the convetional methods.Two groups have a 14 -day course of treatment.Compari-son of angina pectoris and ECG, blood coagulation index, blood rheology,blood lipid, blood lipid, cytokine levels and adverse reac-tions were observed in the two groups.Results The total effective rates of angina and ECG in the observation group were significantly higher than the control group (P <0.05).Prothrombin time (PT), activated partial thrombin time (APTT), and high density lipopro-tein cholesterol (HDL -C) were significantly increased after treatment in the two groups, while fibrinogen (FIB), whole blood viscosi-ty, platelet aggregation, plasma viscosity, total cholesterol (TC),triglyceride (TG), low density lipoprotein cholesterol (LDL -C), interleukin -6 (IL -6), and tumor necrosis factor -α(TNF -α) were significantly decreased (P <0.05).In the observation group, PT, APTT and HDL -C after treatment were significantly higher than the control group (P <0.05), but FIB, whole blood viscosity, platelet aggregation, plasma viscosity, TG, LDL -C, IL -6, TNF -αand TC were significantly lower than the control group (P <0.05).No obvious adverse reactions were found in the two groups.Conclusions Rosuvastatin showed significant clinical curative effect in the treatment of coronary heart disease .The study demonstrated that rosuvastatin can significantly improve coagulation, blood lipids, and blood rheology, and can also significantly reduce micro inflammatory state, which is safe, reliable, and worthy of clinical research.%目的：探讨瑞舒伐他汀治疗冠心病患者疗效观察及对患者凝血、血液流变学、血脂、细胞因子水平的影响。方法104例冠心病患者根据随机分组法随机分为观察组（n ＝52）和对照组（n ＝52）。对照组采用常规对症治疗，观察组在对照组基础上结合瑞舒伐他汀治疗。两组疗程均为14 d。对比分析两组心绞痛和心电图疗效、治疗前后凝血指标、血液流变学、血脂、细胞因子水平变化及不良反应观察。结果观察组总有效率心绞痛和心电图显著高于对照组（P ＜0．05）；两组凝血酶原时间（PT）、活化的部分凝血酶时间（APTT）、高密度脂蛋白胆固醇（HDL －C）治疗后明显增加，而纤维蛋白原（FIB）、全血黏度、血小板聚集、血浆黏度、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL －C）、白介素－6（IL －6）和肿瘤坏死因子－α（TNF －α）显著减少（P ＜0．05）；观察组 PT、APTT、HDL －C 治疗后显著高于对照组（P ＜0．05），而 FIB、全血黏度、血小板聚集、血浆黏度、TC、TG、LDL －C、IL －6、TNF －α显著低于对照组（P ＜0．05）；两组治疗期间均未见明显不良反应。结论瑞舒伐他汀治疗冠心病临床疗效显著，可明显改善患者凝血、血脂、血液流变学功能，且可明显减轻患者微炎症状态，安全可靠，值得临床研究。